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Abstract Metabolomics as one of the most rapidly growing
technologies in the ‘‘-omics’’ field denotes the comprehensive
analysis of low molecular-weight compounds and their
pathways. Cancer-specific alterations of the metabolome can
be detected by high-throughput mass-spectrometric metabo-
lite profiling and serve as a considerable source of new
markers for the early differentiation of malignant diseases as
well as their distinction from benign states. However, a
comprehensive framework for the statistical evaluation of
marker panels in a multi-class setting has not yet been
established. We collected serum samples of 40 pancreatic
carcinoma patients, 40 controls, and 23 pancreatitis patients
according to standard protocols and generated amino acid
profiles by routine mass-spectrometry. In an intrinsic three-
class bioinformatic approach we compared these profiles,
evaluated their selectivity and computed multi-marker panels
combined with the conventional tumor marker CA 19-9.
Additionally, we tested for non-inferiority and superiority to
determine the diagnostic surplus value of our multi-metabo-
lite marker panels. Compared to CA 19-9 alone, the combined
amino acid-based metabolite panel had a superior selectivity
for the discrimination of healthy controls, pancreatitis, and
pancreatic carcinoma patients ½volume under ROC surface
VUSð Þ ¼ 0:891 95% CI 0:794  0:968ð Þ: We combined
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high-throughput mass-spectrometric technique, and a com-
prehensive bioinformatic framework to identify metabolite
panels selective for all three groups in a single approach. Our
results suggest that metabolomic profiling necessitates
appropriate evaluation strategies and—despite all its current
limitations—can deliver marker panels with high selectivity
even in multi-class settings.
Keywords Pancreatic cancer  Metabolomics  Amino
acids  Modeling  Marker panels
Abbreviations
1H NMR Proton nuclear magnetic resonance
(spectrometry)
2D NMR 2-Dimensional nuclear magnetic
resonance (spectrometry)
AU(RO)C Area under the (receiver operator
characteristics) curve
mlogitBMA Bayesian multinomial logit model
averaging
CA 19-9 Carbohydrate antigen 19-9
CAR scores ‘Correlation-adjusted (marginal)
correlation’ scores
CEA Carcinoembryonic antigen
GC–MS Gas chromatography mass
spectrometry
GC/TOF–MS Gas chromatography/time of flight
mass spectrometry
ICAM-1 Intracellular adhesion molecule 1
LC/ESI-MS Liquid chromatography/electrospray
ionization mass spectrometry
LC/LTQ-Orbitrap Liquid chromatography/linear ion trap
combined with an orbitrap (mass
spectrometry)
OPG Osteoprotegerin
PC(A) Principal component (analysis)
TIMP-1 TIMP metallopeptidase inhibitor 1
VUS Volume under (ROC) surface
1 Introduction
Pancreatic cancer is the fourth leading cause of cancer death
in the United States, and most patients diagnosed with pan-
creatic cancer develop clinical symptoms usually late in the
course of the disease (Lowenfels and Maisonneuve 2006).
Therefore, only 20 % of patients can be treated with a
potentially curative therapy and only about 3–5 % survive at
least 5 years (Michl et al. 2006). For these patients, time,
especially the so called ‘biomarker lead time’ between the
onset of asymptomatic cancer still localized to the organ of
origin and clinical diagnosis (Konforte and Diamandis 2012),
is crucially important (Hazelton and Luebeck 2011).
Although recent modeling studies have illustrated that blood-
based biomarkers might provide a successful tool for the early
detection and differentiation of premalignant lesions, sub-
stantial methodological enhancements of unanticipated
extent (Burgess 2012) are still required. Yachida et al. (2010)
demonstrated a latency of about 17 years from the initiating
mutation to pancreatic cancer death. Similarly, Hori and
Gambhir (2011) stated ‘‘that shedding rates of current clinical
blood biomarkers are likely 104-fold too low to enable
detection of a developing tumor within the first decade of
tumor growth’’ and suggested to increase sensitivity and
specificity by introducing multi-marker panels of up to 10
biomarkers. In a proof-of-principle study for evaluating the
utility of multiplexed circulating biomarkers, Brand et al.
(2011) investigated the selectivity of 83 proteins and their
combinations. Two panels consisting of CA 19-9, ICAM-1,
and OPG, as well as CA 19-9, CEA, and TIMP-1 were found
to discriminate pancreatic cancer patients from healthy con-
trol subjects and from patients with benign pancreatic con-
ditions, respectively. Since the cohorts in this study were
compared separately, an integral model encompassing all
three disease states was not obtained. Whereas Brand et al.
(2011) focused on known tumor markers, tumor-associated
peptides, etc., other studies have employed several of the
emerging ‘‘-omics’’ subspecialties, such as proteomics (Fie-
dler et al. 2009), transcriptomics (Zhang et al. 2010), and—as
the probably closest to the ‘‘bedside’’ (Van and Veenstra
2009)—metabolomics (Bathe et al. 2011; Ceglarek et al.
2009; Nishiumi et al. 2010; OuYang et al. 2011; Urayama
et al. 2010; Zhang et al. 2011). The latter bears the chance to
learn from the intricacies that have plagued ‘‘-omics’’
researchers over the last years, standardization (Van and
Veenstra 2009), data processing (Blekherman et al. 2011) and
data interpretation (Kholodenko et al. 2012), amongst others.
In this study, we addressed these challenges by using a
three-class study design. We collected highly standardized
samples of pancreatic cancer patients, subjects with pan-
creatitis, and healthy controls. Following tandem mass
spectrometric metabolite profiling, we evaluated the dif-
ferences between groups and applied Bayesian methodol-
ogy to identify multi-metabolite models as ‘‘meta-
markers’’, which are selective for each of the three study
groups and provide improved diagnostic performance
compared to CA 19-9, the conventional tumor marker.
2 Materials and methods
2.1 Patients and samples
We recruited patients suffering from pancreatic cancer
(n ¼ 40), healthy controls (n ¼ 40), and patients
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hospitalized due to acute pancreatitis (n ¼ 26) at the Uni-
versity Hospital of Leipzig in the context of previously
published studies (Fiedler et al. 2009; Leichtle et al. 2012).
We collected cubital vein fasting samples of cancer
patients and healthy controls in two independent sets.
Additionally, we collected fasting serum samples of 26
patients with pancreatitis as inflammatory control group
(A, C, and D, ntotal ¼ 106; Table 1). We adjusted subjects
according to age and gender and performed blood sampling
from patients before the initiation of specific therapy.
Diagnosis of pancreatic cancer was confirmed by histologic
examination in all cases. Healthy controls showed no evi-
dence of actual disease in physical examination and routine
laboratory testing [alkaline phosphatase, bilirubin, C-reac-
tive protein, CA 19-9, CEA, creatinine, c-glutamyltrans-
ferase, transaminases (Roche Modular, Germany)].
Pancreatitis patients were diagnosed clinically without
proof of pancreatic carcinoma during the study period.
Serum samples were collected and stored (at -80 C)
using standardized techniques and protocols (Baumann
et al. 2005).
2.2 Chemicals, standards and consumables
Methanol and isopropanol (gradient grade) were purchased
from Merck (Darmstadt, Germany). The amino acid iso-
tope labelled standard kit (NSK-A, Cambridge Isotope
Laboratories, Andover, USA) was used as internal stan-
dard. Water (HPLC grade) was obtained from J. T. Baker
(Deventer, Netherlands). The derivatization reagent
3n butanolic HCl was made in-house by mixing 4:1 v/v of
1-butanol (for spectroscopy) from Merck (Darmstadt,
Germany) and acetyl chloride (p.a.) from Sigma-Aldrich
(Steinheim, Germany). 96-well polypropylene microtiter
plates were purchased from Greiner Bio-One (Fricken-
hausen, Germany). Sampling material was obtained from
Sarstedt (Nu¨mbrecht, Germany). For sample storage
450 lL CryoTubesTM were purchased from Sarstedt.
2.3 Sample pretreatment
Sample derivatization was performed according to our
previously described protocols (Brauer et al. 2011).
Shortly, serum samples were diluted 1:10 with methanol
for protein precipitation. After centrifugation we placed
10 lL of the supernatant into 96-well polypropylene
microtiter plates and diluted it with 100 lL of the internal
standard solution. Following evaporation at 70 C for
40 min, we added 60 lL of 3n butanolic-HCl for deriva-
tization at 65 C for 18 min. The residual solution was
again evaporated at 70 C for 40 min and then reconsti-
tuted with 150 lL of the mobile phase (1/1 v/v isopropa-
nol/water). After 15 min of gentle shaking of the microtiter
plate at room temperature, we analyzed the samples by
flow injection analysis (FIA)-tandem mass spectrometry
(MS/MS).
2.4 Tandem mass spectrometry
An API 3000 MS/MS (Applied Biosystems, Germany)
equipped with a Turbo Ion Spray Source (TIS) in combi-
nation with an HTC Pal autosampler and a PE 200 mi-
crogradient pump was used for flow injection analysis
(FIA). 25 lL of the sample were directly injected at a flow
rate of 80 lL/min in an analysis time of 1.5 min. We
detected amino acids by a neutral loss scan of 102 in the
mass range of 130–280 or multiple reaction monitoring
(MRM). Quantitative analysis using internal standards for
26 amino acids was performed using ChemoViewTM 1.4.2
(Applied Biosystems, Germany). A comprehensive over-
view of mass transitions, internal standards, and perfor-
mance data for the different amino acids is summarized in
Brauer et al. (2011).
2.5 Bioinformatic analysis
Statistical analyses were conducted (unless otherwise sta-
ted) using R for Windows (Version 2.14.2) and its related
CRAN packages (http://cran.r-project.org/). We tested data
for normality by the Anderson–Darling test (nortest) and
the gender distribution in the subgroups by the binomial
test (stats). The homogeneity of variances of the quantita-
tive routine laboratory data was evaluated with the
approximative Fligner–Killeen test (stats), whereas the
paired differences were investigated by Games–Howell
testing (script source: http://aoki2.si.gunma-u.ac.jp/R/src/
tukey.R). Three missing CA 19-9 values were imputed by
multiple imputation (MI) with 3 chains of imputation
(which were averaged thereafter), a R^ value of 1.1, and
bootstrap as random imputation method until conversion
(after 7111 iterations). Three pancreatitis samples with
non-random missing data as a consequence of insufficient
sample volume were excluded from further analysis. The
selectivity of single amino acid concentrations was asses-
sed in all disease states simultaneously via the volume
under ROC surface (VUS), which is the three-dimensional
analogue of AUROC analysis (Nakas and Yiannoutsos
2004). The VUS’ and their associated confidence intervals
were calculated nonparametrically using B ¼ 2; 000 boot-
straps and 50 k subdivisions on the amino acid concen-
trations (DiagTest3Grp). As we assumed a high degree of
collinearity in the amino acid concentrations, we computed
Kendall’s s as well as its Hochberg-adjusted significance
(ltm, corrplot) and plotted the correlation matrix (Fig. 1).
Based on our previous results indicating that marker
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models comprising combinations of different amino acids
and/or CA 19-9 might be superior to single amino acids
and/or CA 19-9 with respect to their selectivity (Leichtle
et al. 2012), we also evaluated combined models. These
models consisted on the one hand of the conventional
tumor marker CA 19-9 combined with different principal
components (PC1, PC2, …) of the different amino acid
concentrations to control for multicollinearity, which is a
significant constraint on variable selection (Leigh 1988).
On the other hand we also combined CA 19-9 with mere
amino acid concentrations to avoid potentially unnecessary
transformation steps prior to modeling. After Yeo–Johnson
transformation (car) of the amino acid concentrations, we
generated PCs (princomp and factoMineR), from which the
first six PCs had eigenvalues [1.0 and cumulatively cov-
ered 78.7 % of the variance. For the modeling in a three-
state design, we merged sample set A with C and obtained
one tumor group, one control group and one pancreatitis
group (set D). In the second step we used CA 19-9 alone
and combined with the PCs of the amino acid concentra-
tions as well as with mere concentrations for Bayes-aver-
aged multinomial logit modeling [mlogitBMA,
bic.mlogit(mlogitBMA)] using Begg and Gray approxi-
mation. We validated the latter model by CAR [‘Correla-
tion-Adjusted (marginal) coRrelation’] scores (care)
assuming empirical values of 1.0, 0.3, and 0.1 as responses
of the pancreatic carcinoma, the healthy control, and the
pancreatitis groups, respectively, in a CAR model trun-
cated to a number of variables comparable to the penalized
multinomial logit model. We computed the VUS for the
four predictors, namely CA 19-9, the PCA-based mlo-
gitBMA-predictor (PCA), the amino acid concentration-
based mlogitBMA-predictor (AA), and the amino acid
concentration-based CAR-model-predictor (CAR) analo-
gously to the VUS values of the amino acid concentrations.
The ROC surface plots (Fig. 2) were drawn using MAT-
LAB (The MathWorks, Natick, MA, USA). Since signifi-
cant differences of the VUS between predictors and
CA 19-9 do not imply inferiority or superiority, we per-
formed non-inferiority and superiority testing applying
bootstrap techniques on DVUS (Bouter ¼ 1; 000, boot,
Binner ¼ 1; 000, DiagTest3Grp, UBELIX Cluster of the
University of Bern). We constructed the corresponding CIs
and tested for the overlap of D0 and the DVUS’ CI according
to the methods proposed by Liu et al. (2006), Tunes da
Silva et al. (2009), and Lesaffre (2008) at a predefined d
level of 5 % which was considered to be medically rea-
sonable designing this and a previous study (Leichtle et al.
2012). We visualized the performance data in a forest plot
[Fig. 3, forestplot(rmeta), R version 2.15.0, cf. Mascha
(2010)].
2.6 Ethics
The study was approved by the Ethics Committee of the
Medical Faculty of the University of Leipzig (Reg.
No. 013-2005) and it fulfills the requirements of the Hel-
sinki declaration. All study subjects gave written informed
consent to participate in the study.
3 Results and discussion
3.1 Descriptives
We collected serum samples of 40 (20 males/20 females)
pancreatic carcinoma patients, 26 (22 males/4 females,
Pbinomial ¼ 0:0005) pancreatitis patients, and 40 (20 males/
20 females) healthy controls. Table 1 displays the distri-
butions of age, BMI, UICC cancer staging of the patients,
the CA 19-9, bilirubin, and HbA1c concentrations in the
three different sample sets. Of 26 amino acid concentra-
tions, we found only four (arginine, glutamic acid, phen-
ylalanine, and tryptophan) unaltered between the study
groups (Table 2). Several amino acid concentrations were
non-normally distributed. In order to detect sample set-
specific alterations in the values, we also compared the
amino acid concentrations of the tumor patients and the
healthy control group between the two sample sets and
found no significant differences (Table 2).
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Fig. 1 Correlation matrix of the amino acid concentrations (see
Murdoch and Chow 1996 for details). In the upper right part
Kendall’s s is displayed according to the right-hand legend, in the
lower left part the corresponding (1 - P) values are limned to
illustrate the significance of the correlation (cf. legend at the bottom).
For compound abbreviations, see Table 2
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3.2 Correlations
We evaluated the multicollinearity of the amino acid
concentrations by generating their correlation matrix
(Kendall’s s and its Hochberg-adjusted significance).
Kendall’s s values ranged between -0.516 (aspartic acid
with glutamine) and 0.709 (threonine with glutamine), the
P values between 0.001 and 0.97 (Fig. 1).
3.3 Modeling
We hypothesized that combinatory markers including
several amino acids and/or CA19-9 might have additive or
even multiplicative effects and thus be superior to single
amino acids and/or CA 19-9 in diagnostics of pancreatic
cancer (Brand et al. 2011). Therefore, in addition to eval-
uating the single VUS of the amino acid concentrations, we
also generated models based on CA 19-9 combined with
PCs and Bayesian multinomial logit model averaging
(mlogitBMA) as well as on CA 19-9 conjoined with amino
acid concentrations. Furthermore, we used models based on
CAR scores to evaluate their three-class selectivity in
comparison with that of single amino acid concentrations
and CA 19-9 as a validation method for the mlogitBMA
Fig. 2 Three-dimensional ROC surfaces depicting true class rates of
CA 19-9 alone (a), the mlogitBMA predictor model based on PCAs
and CA 19-9 (b), the mlogitBMA predictor model based on amino
acid (AA) concentrations and CA 19-9 (c), and the CAR-score based
predictor model (d, See Section 2) when the three classes/states are
assessed simultaneously. The axes represent true class rates for
healthy controls (H), pancreatitis patients (P), and pancreatic carci-
noma patients (C)
Predictor
CA19-9
s PCA
s AA
s CAR
 Mean
0%
13.72%
69.29%
65.12%
 or 's 90%CI
(-5% – +5%)
(-16.36% – 46.14%)
(49.02% – 86.88%)
(45.83% – 83.74%)
-20 0 20 40 60 80 100
% VUS
Fig. 3 Forest plot of the DVUS based on CA 19-9s VUS (D0, 0.528) as
reference with the predefined ±5 % d as horizontal bars (a).
Additionally, the DVUS values of the predictors PCA, AA, and CAR
are displayed with their (100 - 2 d) % bootstrap CIs (b, See
Section 2)
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models. The best PC-based mlogitBMA-model comprised
CA 19-9 and PC2. The best amino acid concentration-
based mlogitBMA-model contained CA 19-9 and aspartic
acid, which both were also contained in the truncated
amino acid concentration-based CAR score-model. To
evaluate the selectivity of both, amino acid concentrations
and modeled predictors, we computed their volume under
the ROC surface (VUS) (Table 3). The VUS of the amino
acid concentrations spanned from 0.180 (arginine, 95 % CI
0.106–0.270) to 0.850 (glutamine, 95 % CI 0.761–0.929).
The VUS of CA19-9 was 0.528 (95 % CI 0.400–0.654),
and the predictors PCA, AA, and CAR had VUSs of 0.604
(95 % CI 0.446–0.745), 0.891 (95 % CI 0.794–0.968), and
0.871 (95 % CI 0.776–0.952), respectively. For a random
classifier, the VUS could be geometrically determined
(Landgrebe and Duin 2007) with a value of 1:6: To illus-
trate the selectivity of CA 19-9 and the predictors, we
generated true class rate-plots depicting the ROC surface
(Fig. 2).
3.4 Non-inferiority and superiority testing
Since it is generally accepted that significant difference
alone might not be an adequate measure of non-inferiority
or superiority, we sequentially tested for both with an a
priori-defined acceptance criterion (equivalence limit) of
d ¼ 5% DVUS. We computed the lower and upper limits of
the (100 - 2d) % bootstrap confidence interval of the
estimated DVUS as proposed by Liu et al. (2006). The
results are shown in Fig. 3. Following the criteria by
Table 2 Inter-group significance (P values) of the differences in CA 19-9 and amino acid concentrations as evaluated by Games–Howell testing
and the homogeneity of variances as determined by Fligner–Killeen testing (column P)
Compound Ap:Ac Ap:Cpa Ap:Cc Ap:D Ac:Cp Ac:Cca Ac:D Cp:Cc Cp:D Cc:D P
CA19-9b 0.003 0.692 0.003 0.006 0.030 0.753 0.058 0.032 0.069 0.107 0.000
Glutamine (Gln); (CID 5961) 0.000 0.239 0.000 0.000 0.007 0.962 0.000 0.012 0.000 0.000 0.000
Lysine (Lys) (CID 5962)b 0.791 0.876 0.971 0.029 0.319 0.972 0.005 0.523 0.259 0.004 0.865
Hydroxyproline (OH.Prol) (CID 5810) 0.050 0.932 0.102 0.996 0.271 1.000 0.015 0.371 0.755 0.043 0.706
Pipecolic acid (PiPA) (CID 849) 0.001 0.245 0.000 0.020 0.605 0.982 0.000 0.360 0.002 0.000 0.371
Abscisic acid (Aba) (CID 5280896) 0.440 0.999 0.545 0.000 0.530 0.999 0.000 0.646 0.000 0.000 0.000
Alanine (Ala) (CID 5950) 0.067 1.000 0.383 0.998 0.019 0.917 0.118 0.212 0.989 0.547 0.447
Arginine (Arg) (CID 6322) 0.999 0.998 0.950 0.932 1.000 0.991 0.980 0.994 0.984 1.000 0.759
Aspartic acid (Asp) (CID 5960) 0.121 0.982 0.120 0.000 0.138 1.000 0.000 0.136 0.000 0.000 0.000
Carnosin (CID 439224)b 0.411 0.377 0.216 0.000 1.000 1.000 0.000 0.997 0.000 0.000 0.000
Citrulline (Cit) (CID 9750) 0.095 0.994 0.679 1.000 0.160 0.330 0.037 0.884 0.989 0.523 0.481
Glutamic acid (Glu) (CID 33032) 0.881 0.266 0.757 0.602 0.101 0.998 0.224 0.075 0.897 0.168 0.000
Glycine (Gly) (CID 750) 0.890 1.000 0.984 0.113 0.831 0.993 0.011 0.966 0.079 0.019 0.879
Histidine (His) (CID 6274)b 0.995 1.000 0.999 0.068 0.987 0.971 0.087 1.000 0.009 0.057 0.000
Leucine/Isoleucine (Leu.Ile)
(CID 6106/CID 6306)
0.033 0.999 0.040 0.134 0.046 1.000 0.971 0.056 0.183 0.954 0.883
Methylhistidine (MeHis) (CID 64969) 0.049 0.907 0.289 0.000 0.623 0.877 0.000 0.956 0.000 0.000 0.001
Methionine (Met) (CID 6137)b 1.000 0.999 1.000 0.604 0.978 1.000 0.188 0.996 0.021 0.314 0.050
Ornithine (Orn) (CID 6262) 0.199 0.531 0.708 0.015 0.953 0.846 0.000 0.998 0.001 0.002 0.722
Phenylalanine (Phe) (CID 994)b 0.962 0.995 0.967 1.000 1.000 1.000 0.975 1.000 0.993 0.972 0.069
Proline (Pro) (CID 8988) 0.051 0.957 0.049 0.022 0.163 1.000 0.971 0.153 0.187 0.957 0.009
Sarcosine (Sarc) (CID 1088)b 0.272 0.507 0.953 0.786 0.002 0.681 0.999 0.119 0.173 0.967 0.212
Serine (Ser) (CID 5951) 0.091 0.380 0.011 0.018 0.931 0.816 0.998 0.382 0.746 0.891 0.446
Taurine (Tau) (CID 1123) 0.003 0.053 0.016 0.001 0.595 1.000 0.000 0.784 0.000 0.000 0.091
Threonine (Thr) (CID 6288) 0.008 0.886 0.051 0.000 0.086 1.000 0.000 0.246 0.000 0.000 0.000
Tryptophan (Trp) (CID 6305)b 0.589 0.705 0.151 0.058 0.999 1.000 0.945 0.985 0.798 0.931 0.189
Tyrosine (Tyr) (CID 6057) 0.041 0.818 0.056 1.000 0.421 1.000 0.050 0.510 0.840 0.068 0.855
Valine (Val) (CID 6287) 0.000 0.331 0.016 0.475 0.116 0.999 0.000 0.316 0.029 0.002 0.084
Sets A, C, and D (only pancreatitis) with pancreatic carcinoma patients (p) and controls (c). P values\0.05 are shown as bold numbers. Amino
acids with no significant difference in any group comparison are displayed in italics. Metabolites are identified by their PubChem Compound ID
(CID)
a Comparisons of subjects of the same class in different sets
b Signifies deviation from normal distribution in at least one subgroup as evaluated by Anderson–Darling testing
Metabolite models in a three-class setting 683
123
Mascha (2010) we deduced non-inferiority for predictors
AA and CAR compared to CA 19-9. Furthermore, superi-
ority of the AA and CAR predictors over CA 19-9 alone
was derived in a second step, since the lower CI of DVUS
was positive.
‘‘The ideal biological marker(s) for cancer risk assess-
ment and early detection must have high sensitivity and
specificity, be found in a biosample obtained using mini-
mally invasive procedures, and be analyzed using a high-
throughput, cost-effective assay.’’ These requirements
stated by Van and Veenstra (2009) are challenging to ful-
fill. Particularly, in the case of pancreatic cancer diagnos-
tics this challenge is even bigger due to the number of
differential diagnoses, which are difficult to discern from
malignant disease even for experienced clinicians (Gong
et al. 2012). Furthermore, chronic pancreatitis patients also
have a 15-fold higher risk than the general population to
develop pancreatic cancer (Huggett and Pereira 2011). In
order to identify biomarkers capable of discriminating
different disease states, we designed a study including
pancreatic cancer patients and healthy controls of two
independently collected sample sets as well as an addi-
tional group of pancreatitis patients, since the principal
feasibility of the metabolomic approach to pancreatic
cancer was recently shown (Bathe et al. 2011; Tesiram
et al. 2012; Zhang et al. 2012). Samples were processed
following highly standardized preanalytical protocols and
applying a routinely used tandem mass spectrometric
technique. By comparing the sample groups, we found 22
of 26 amino acids altered in at least one out of ten possible
comparisons. The number of different metabolites is
comparable to that given by Bathe et al. (2011) who found
22 of 58 metabolites significantly different between
malignant and benign pancreatic disease applying 1H NMR
and 2D NMR spectroscopy, with OuYang et al.’s (2011)
1H NMR spectroscopy results showing significant altera-
tions of at least 8 metabolites between only 17 pancreatic
carcinoma patients and 25 healthy controls. It is consistent
with Urajama et al.’s (2010) combined GC/TOF-MS, LC/
ESI-MS, and LC/LTQ-Orbitrap study revealing 26 signif-
icantly different metabolites in a comparison of 5 pancre-
atic cancer samples and 5 mixed pancreatitis/healthy
controls, and with Nishiumi et al.’s (2010) GC–MS
investigations based on 21 pancreatic cancer patients and 9
healthy volunteers identifying 18 of 60 metabolites as
significantly different. In addition to the inter-class com-
parisons of the different sample sets, we also evaluated the
inter-sample set differences in the respective classes (can-
cerA - cancerC and controlA - controlC) and found no
significant differences. Since the sample groups were
homogeneous, we preferred a joint analysis in the modeling
approach over a split-half design to keep the degree of
random error as low as possible (Knottnerus and Muris
2003; Ransohoff and Gourlay 2010). Although the previ-
ously published metabolome profiling studies of pancreatic
carcinoma are heterogeneous regarding the used mass-
spectrometric techniques and the studied metabolites, they
all share canonical variance-based evaluation strategies
with two-class comparisons. Additionally, only one of the
studies (Bathe et al. 2011) assessed the selectivity (e.g.
AUROC or VUS analyses) of the marker metabolites. Our
aim was to perform a comprehensive data analysis that also
allows a clear interpretation of the diagnostic value of the
markers (Leichtle et al. 2012). To this end, we imple-
mented four unexampled features in our bioinformatic
pipeline: (1) The computation of three-class VUS values of
the single amino acid concentrations as an integral selec-
tivity measure, (2) a Bayesian multinomial logit model
Table 3 Volume under receiver operator characteristics curve (VUS)
and 95 % confidence intervals of the amino acid and CA 19-9 con-
centrations as well as of a random classifier [cf. Landgrebe and Duin
(2007)] with respect to the discriminatory power between pancreatic
cancer patients, healthy controls, and pancreatitis patients
Compound VUS Low 95 %CI High 95 %CI
Gln 0.8500 0.7606 0.9288
Thr 0.7531 0.6431 0.8581
Asp 0.7156 0.6006 0.8225
PiPA 0.6961 0.5934 0.7976
Aba 0.6305 0.5097 0.7461
Tau 0.6128 0.4869 0.7296
MeHis 0.5946 0.4647 0.7224
His 0.5636 0.4328 0.6915
Carnosin 0.5509 0.4233 0.6695
CA19-9 0.5282 0.3996 0.6536
Val 0.5246 0.405 0.6493
Met 0.4966 0.3685 0.6231
Orn 0.4663 0.3528 0.5928
Lys 0.4375 0.3299 0.5561
Gly 0.4096 0.2969 0.5313
Tyr 0.3457 0.2353 0.4749
OH-Prol 0.3397 0.233 0.4562
Ser 0.3239 0.2228 0.4349
Leu/Ile 0.3157 0.217 0.4305
Cit 0.2845 0.1789 0.4022
Trp 0.2791 0.1789 0.3922
Pro 0.2758 0.1705 0.3957
Sarc 0.2607 0.1547 0.3822
Ala 0.2591 0.1677 0.3607
Phe 0.232 0.145 0.3395
Glu 0.2273 0.1419 0.3164
Arg 0.1801 0.1063 0.2698
Random 1:6 (1=6)
For compound abbreviations, see Table 2
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averaging procedure to extend the previously used bino-
mial logistic regression modeling (Leichtle et al. 2012) on
the three-class study design to generate multi-marker
panels (including CA 19-9), (3) the VUS-based analysis of
the panel predictors, and, finally, (4) their non-inferiority
and superiority determination. The VUS values of the
single amino acid concentrations ranged from 0.18 slightly
above a random classifier to 0.85 (glutamine), which is
close to the best panel predictors. As none of the previous
metabolite profiling studies on pancreatic cancer performed
VUS analysis, we can only rely on the utterly inconsistent
P values they present, in Urayama et al.’s (2010) case
0.000021, or in Nishiumi et al.’s (2010) 0.97 for glutamine.
CA 19-9 alone reached the 10th rank, which is probably
attributable to its low selectivity between benign and
malign pancreatic diseases (Fig. 2a). Since our previous
investigations (Leichtle et al. 2012) indicated a high degree
of multicollinearity in the amino acid concentrations,
which is known to impede many feature selection tech-
niques (Jesneck et al. 2009; Leigh 1988), we set up a
Kendall’s correlation matrix to visualize the multicolline-
arity and its significance. As expected, the full range of
correlation spanned from -0.516 to 0.709, which sup-
ported the inclusion of the frequently recommended PC-
based analysis approach, albeit it has been shown that
variance-based techniques might not always yield optimal
predictors (Leichtle et al. 2012). To compute robust pre-
dictive multi-metabolite marker panels, we combined
CA 19-9 and the PCs as well as CA 19-9 and the mere
amino acid concentrations and used a Bayesian multi-
nomial logit model averaging procedure for our categorical
three-class study design (Robin et al. 2009). The first
model consisted of CA 19-9 and PC2 providing a two-
marker ‘‘panel’’ predictor (PCA) with a VUS of 0.604. The
omission of PC1 and preference of PC2 with less contri-
bution to explained variance during the mlogitBMA pro-
cedure is an astounding finding possibly reflecting a
predilection of variables sharing covariance with CA 19-9.
The second model based on amino acid concentrations
included CA 19-9 and aspartic acid providing a two-mar-
ker ‘‘panel’’ predictor (AA) with a VUS of 0.891. Our
results indicate that CA 19-9 provides the selectivity
mainly for the discrimination between healthy controls and
pancreatic cancer patients (Table 2), whilst aspartic acid
predominantly contributed to the identification of pancre-
atitis patients. Nishiumi et al. (2010) reported a borderline
significant P value of 0.075 for aspartic acid, whereas
Urayama et al. (2010), OuYang et al. (2011) and Bathe
et al. (2011) did not mention significant differences. Our
results and panel predictors, however, require extremely
cautious interpretation since in a previous study an ana-
lytical variability [25 % was observed for aspartic acid
(Brauer et al. 2011). On the other hand, regarding the
substantial impact of especially pancreatic disease on
nutrition, it was not unexpected to find models different to
those of our previous study on colorectal cancer (Leichtle
et al. 2012). The mechanisms disturbing amino acid
homeostasis and enabling the discrimination of pancreatic
cancer patients from pancreatitis patients on the basis of
metabolite profiles are not entirely elucidated. Schrader
et al. (2009) suggested—apart from malnutrition—mainly
inflammatory effects and pointed at the inverse relationship
between the circulating amino acid concentrations and the
degree of inflammation present e.g. in hemodialysis
patients. Whether increased tumor-associated proteolytic
activity (Findeisen and Neumaier 2012) contributes not
only to the generation of specific peptide decay profiles,
but also to the specificity of the amino acid profiles is still
unknown. To validate our results and the Bayesian mod-
eling approach, we also applied model selection techniques
based on CAR scores (Zuber and Strimmer 2011) as a non-
Bayesian linear alternative. Since our study covered
three—more or less—independent classes, we could nei-
ther rely on a binary (CAT score) nor on a metric (CAR
score) response. Therefore we assumed empirical values of
1.0, 0.3, and 0.1 as ‘‘responses’’ of the respective groups
while acknowledging that such a procedure might be
somewhat artificial and not necessarily justified by the
underlying pathophysiology. To gain a comparable number
of model variables as in the penalized mlogitBMA-model
and thereby an at least limited comparability, we used a
two-predictor CAR model including CA 19-9 and aspartic
acid. The CAR panel predictor had a VUS of 0.871 similar
to the value obtained with the Bayesian modeling
approach. As the final evaluation step, we performed a two-
step non-inferiority and superiority testing based on the
bootstrapped DVUS and on a ± d equivalence range of 5 %
as outlined in a previous study (Leichtle et al. 2012).
CA 19-9’s VUS ± d served as reference we tested the
other predictors’ DVUS against. In the first step, we
observed non-inferiority only for the AA and CAR panel
predictors, but not for the PCA panel predictor, whereas in
the second step, we determined superiority of AA and CAR
panel predictors (Fig. 3). These encouraging results indi-
cate an improved selectivity of the models compared to
CA 19-9 alone. Our study has several limitations to be
considered. First, we merged the sample sets A and C to
keep the degree of random error as low as possible in our
modeling analysis (Knottnerus and Muris 2003). However,
the ‘‘external’’ validity of the results could not thus be
evaluated (Ransohoff and Gourlay 2010). Therefore, sub-
sequent studies are necessary in order to assess the gen-
eralizability of our predictor models. Second, due to high
preanalytical standardization and refinement of our bioin-
formatic methodology, the variability of the analytical
method itself might have become the main source of bias.
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With our study design and evaluation strategy, we probably
have reached an analytical boundary, that still requires
substantial improvements (Hori and Gambhir 2011).
Therefore, new analytical techniques are necessary to reach
both, superior sensitivity and stability at the same time. The
third limitation of the study originates from the strong
penalization of our Bayesian modeling approach: The
predictor panels generated by the mlogitBMA procedure
were both two-component panels consisting of CA 19-9
and another variable. Especially in the case of PC-based
modeling and the selection of the second PC while leaving
out the first, a considerable amount of selectivity might
have been lost. On the other hand, the amino acid con-
centration-based model was superior in selectivity [without
taking misclassification costs into account (Klawonn et al.
2011)], suggesting that PCs might not serve as optimal
modeling variables when Occam’s razor is strictly availed.
Finally, rather than proposing a superior diagnostic
metabolite model or ‘‘meta-marker’’ our results suggest
that our bioinformatic framework combined with a meth-
odology refined to sufficient sensitivity and stability might
provide a valuable diagnostic tool for metabolic profiling
even in the three-class differentiation dilemma of health,
inflammation, and malignancy.
4 Short summary
Multi-marker panels have been suggested to improve the
selectivity of pancreatic cancer diagnostics and its differ-
entiation from various benign lesions. However, a com-
prehensive framework for the statistical evaluation of
marker panels in a multi-class setting has not yet been
established.
Using a disease model encompassing pancreatic cancer,
pancreatitis, and healthy controls, 106 standardized serum
samples, and metabolic profiling, we generated models to
discriminate between the three study groups.
Multi-marker models are superior to the conventional
tumor marker CA 19-9 in simultaneously differentiating
between pancreatic cancer, pancreatitis, and healthy
controls.
Our comprehensive bioinformatic approach provides a
novel framework to address a common diagnostic chal-
lenge, and thus paves the way for biomarker validation in a
clinical three-class setting.
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